Maximus Fell 34% Because a Six-Month Performance Bonus Got Paused. That's the Bull Case.

Everyone is right that Maximus looks stuck. Revenue keeps shrinking, growth is hard to find, and the stock is down more than a third this year to about $56, trading near eight times trailing earnings — effectively abandoned by a market that has decided a "profitable but boring" government contractor belongs off the radar.

The problem is what did the damage. The dominant, dated, quantified event was a single six-month pause. That should change the read on the whole stock: not "cheap for a reason," but "cheap for a reason scheduled to expire."

The headline problem is 35 cents

Maximus runs unglamorous public machinery: Medicaid and health-insurance enrollment, welfare-to-work programs, and — through its Veterans Evaluation Services arm — the medical-disability exams the VA needs before it can process a claim. About 55% of its revenue comes from U.S. federal agencies, so one agency's decision can move the entire company.

In August the VA paused the performance incentives tied to the disability-exam program from July through the end of 2026. Management was unusually precise about the cost: those incentives had contributed roughly 35 cents a share in each of the year's first three quarters, matching the 35-cent cut to its fiscal-2026 profit outlook, which now sits at $7.90 to $8.20 a share. Revenue guidance was left untouched.

Do the arithmetic. The whole "broken company" narrative is anchored to an amount equal to about 4% of the roughly $8 a share Maximus still expects to earn this year — an item management has quantified, calls temporary, and expects to reverse when the pause lifts in January. The stock has been repriced as though that pause were permanent and structural: the first act of a government determined to squeeze the vendor out of its margins.

The "coasting" charge is backwards

The complaint that landed Maximus on the "profitable but skip it" list is the familiar one: revenue is flat and the free-cash-flow margin is thin — profitability that, the argument goes, will not build a fortress before a customer or a competitor takes it back. Bezos's phrasing — your margin is my opportunity — is the whole thesis.

The latest quarter is the opposite of coasting. In fiscal Q3, revenue fell 5.2% from a year earlier, yet GAAP earnings per share rose 4.8% and adjusted EPS rose 2.8%, as automation and cost cuts pushed operating margin to 12.6% and gross margin up six-tenths of a point. A business that holds, even grows, its margin while volumes shrink is not a complacent incumbent. It is a machine making the dollars it has go further — which is the wrong-metric trap running in reverse. The crowd sees flat sales and stops reading; the number that actually governs this investment is whether the economics survive a government that keeps re-pricing them.

On durability, the demand itself keeps getting renewed: Veterans Evaluation Services was re-awarded its domestic exam regions through 2026 — the very program at the center of the scare is the one being re-signed.

What the price already assumes

From the balance sheet, this is not a distressed asset: 21 straight years of dividends, a yield around 2.3%, a payout near 18% of earnings, roughly 13.5% return on invested capital, and net leverage near two times, inside the company's own target. The valuation looks cheap even against related services — Cigna trades around 11.6 times trailing earnings, Elevance near 18 times, while Maximus sits at about eight.

Now the honest objection, because it is what separates a real inversion from a clever one. The government is not a normal customer. It is a near-monopsony: it does not switch like a consumer, it rewrites the contract. The VA pause is exactly that power being flexed, and the fear was never the six months — it is the precedent. If Washington decides the economics of human-services vendors are not sacred, then eight times earnings is not a floor; it is merely a smaller drop on the way down.

That fear is real. It is also, at eight times earnings, largely the price. The market has already answered the question "is this permanently broken?" The evidence for permanent is a six-month pause worth about 4% of earnings.

Both sides get a test with dates attached. The VA pause ends December 31; management points to collections accelerating in July and a receivables backlog that should unwind by the fiscal-year close, with days-sales-outstanding falling back under 70 from 98; and it expects to return to mid-single-digit organic growth this quarter and into fiscal 2027. If those land, the stock does not need to become loved. It needs only to stop becoming worse than the price already assumes.

Being right that Maximus is cheap will not protect a career. Government-contractor pessimism is now consensus: embedded, comfortable, safe to repeat. That is exactly the positioning that leaves a 21-year dividend payer underowned when a six-month pause — already quantified, already priced — simply runs its course. The question is whether a temporary 35-cent hit to an $8 earnings stream is worth a permanent derating. The market says yes. The math says the market has paid a very expensive premium for its own certainty.